Michelle P. Aranha

Also affiliated with Boston University, Boston Medical Center, Harvard University, Dana-Farber Cancer Institute, Massachusetts Institute of Technology

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma”.

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Cancer Cell(2022)10.1016/j.ccell.2022.10.017

N/A

0.626DataRank · unranked

64 citations

Michelle P. Aranha, Robert Redd, Joanna Bagińska, Nicholas J. Haradhvala, Margaret Hallisey +34 more

Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein–derived peptides

Journal of Biological Chemistry(2020)10.1074/jbc.ra119.011258

N/A

0.518DataRank · unranked

12 citations

Thomas A. Penfound, Jay Spencer, Rupesh Agarwal, Jerome Baudry, James B. Dale +2 more

Cross-reactive immunogenicity of group A streptococcal vaccines designed using a recurrent neural network to identify conserved M protein linear epitopes

Vaccine(2021)10.1016/j.vaccine.2021.01.075

N/A

0.373DataRank · unranked

11 citations

T. A. Penfound, Sanaz Salehi, Michelle P. Aranha, Lauren E. Wade, Rupesh Agarwal +4 more

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

medRxiv(2024)10.1101/2024.04.19.24306082

N/A

0.343DataRank · unranked

6 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial

Nature Communications(2025)10.1038/s41467-024-55308-5

N/A

0DataRank · unranked

14 citations

Michelle P. Aranha, Robert Redd, Michael Timonian, Sophie Magidson, Elizabeth D. Lightbody +17 more

Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s Macroglobulinemia

Nature Communications(2025)10.1038/s41467-025-56323-w

N/A

0DataRank · unranked

13 citations

Yoshinobu Konishi, Daniel Heilpern-Mallory, Ting Wu, Nicholas Tsakmaklis, Michelle P. Aranha +17 more

Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine

Vaccine(2023)10.1016/j.vaccine.2023.08.026

N/A

0DataRank · unranked

8 citations

Michelle P. Aranha, Thomas A. Penfound, Sanaz Salehi, Jeremy C. Smith, James B. Dale

Dissecting Phenotype from Genotype with Clinical Isolates of SARS-CoV-2 First Wave Variants

Viruses(2023)10.3390/v15030611

N/A

0DataRank · unranked

3 citations

Evan P. Williams, Yi Xue, Piroon Jenjaroenpun, Thidathip Wongsurawat, Amanda Smith +15 more

Systematic characterization of therapeutic vulnerabilities in Multiple Myeloma with Amp1q reveals increased sensitivity to the combination of MCL1 and PI3K inhibitors

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.01.551480

N/A

0DataRank · unranked

2 citations

Elizabeth D. Lightbody, Mairéad Reidy, Junko Tsuji, Michelle P. Aranha, Daniel Heilpern-Mallory +15 more